Showing 2471-2480 of 3223 results for "".
- Visionix Unveils the VX 610 Automated Fundus Camerahttps://modernod.com/news/visionix-unveils-the-vx-610-automated-fundus-camera/2482407/Visionix USA announced the launch of the VX 610 non-mydriatic automated fundus camera. The VX 610 boasts a range of automated features, including auto alignment, auto focus, and auto capture. This level of automation not only streamlines the imaging process but also redu
- Ocutech Announces Release of SideSight Ultrasonic Sensor Device for Homonymous Hemianopiahttps://modernod.com/news/ocutech-announces-limited-release-of-sidesight-ultrasonic-sensor-device-for-homonymous-hemianopia/2482405/Ocutech announced the limited first release of its new ultrasonic sensor device, the SideSight. Developed in collaboration with experts in electrical, software, and mechanical engineering, Ocutech says the SideSight is designed to assist individuals who have experienced loss of side vision, a con
- FDA Notifies Ocular Therapeutix that SOL-R Trial is Appropriate as a Registrational Study in Wet AMDhttps://modernod.com/news/fda-notifies-ocular-therapeutix-that-sol-r-trial-is-appropriate-as-a-registrational-study-in-wet-amd/2482388/Ocular Therapeutix announced that it has received a written response from the FDA that the phase 3 SOL-R clinical trial is appropriate for use as the company’s second adequate and well controlled study of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the
- Annexon Provides Update on ARCHER II Global Registrational Program in GAhttps://modernod.com/news/annexon-provides-update-on-archer-ii-global-registrational-program-in-geographic-atrophy/2482386/Annexon announced patient dosing was initiated in the global pivotal phase 3 ARCHER II trial evaluating ANX007 for the treatment of geographic atrophy (GA). The company says the trial is the only GA pivotal program utilizing visual protection as the global regulatory-aligned primary end
- Enrollment Begins for Ocular Therapeutix’s Axpaxli Phase 3 SOL-R Wet AMD Studyhttps://modernod.com/news/ocular-therapeutixs-axpaxli-phase-3-sol-r-wet-amd-study-begins-enrollment/2482382/Ocular Therapeutix announced that the first patients have been enrolled in the phase 3 SOL-R clinical trial evaluating repeat dosing of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of patients with wet age-related macular degeneration (wet AMD). Accor
- Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term DME Studyhttps://modernod.com/news/vabysmo-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-dme-study/2482363/At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden, Genentech announced new, 4-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo (faricimab-svoa) was well tolerated in people with diabetic mac
- PulseMedica Raises $12 Million to Advance Eye Floater Imaging and Treatment Technologyhttps://modernod.com/news/pulsemedica-raises-12-million-to-advance-eye-floater-imaging-and-treatment-technology/2482360/PulseMedica announced that it has raised an aggregate of $12 million to date in investment as part of their pre-Series A financing round. This investment allowed PulseMedica to generate initial results from their preclinical and clinical studies, and will continue to accelerate the clinical valid
- EMA’s CHMP Issues Negative Opinion of Syfovre for GA; Apellis to Seek Re-Examinationhttps://modernod.com/news/emas-chmp-issues-negative-opinion-for-syfovre-for-ga-apellis-to-seek-re-examination/2482336/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of Apellis’s intravitreal pegcetacoplan for the treatment of geographic atrophy (GA). “Although th
- Azura Ophthalmics Enrolls First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with MGDhttps://modernod.com/news/azura-ophthalmics-enrolls-first-patient-in-phase-3-clinical-trial-for-azr-md-001-in-patients-with-mgd/2482307/Azura Ophthalmics announced that the first patient has been enrolled in the ASTRO study—a phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of meibomian gland dysfunction (MGD). "AZR-MD-001 has already dem
- Zeiss Announces OCT Enhancements to Cirrus 6000https://modernod.com/news/zeiss-announces-oct-enhancements-to-cirrus-6000/2482299/Zeiss Medical Technology announced enhancements to the Cirrus 6000 designed to allow for a more efficient and data-driven workflow for ophthalmologists. The device is supported by the largest OCT reference database in the US market, according to Zeiss, as well a